Drug intelligence / Profile preview

tafetinib

Development stage: Phase 1
Lead developer: Nanjing Yoko Biomedical
Modality: Small Molecules
Administration: Oral

Overview

Tafetinib is an oral, multitargeted tyrosine kinase inhibitor developed by Nanjing Yoko Biomedical Co., Ltd. It functions by inhibiting the Vascular Endothelial Growth Factor Receptor (VEGFR). This drug is being investigated for its safety, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors.

Targets

VEGFR (VEGFR family)

Beyond the preview

Go deeper on tafetinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tafetinib.

Explore the full profile